Impact of the Underlying Mutation and the Route of Vector Administration on Immune Responses to Factor IX in Gene Therapy for Hemophilia B
Open Access
- 1 October 2009
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 17 (10), 1733-1742
- https://doi.org/10.1038/mt.2009.159
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Improved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene TransferHuman Gene Therapy, 2009
- Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapyBlood, 2009
- Cytotoxic T Lymphocyte Responses to Transgene Product, Not Adeno-Associated Viral Capsid Protein, Limit Transgene Expression in MiceHuman Gene Therapy, 2009
- Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific TregsJCI Insight, 2008
- Recombinant adeno-associated virus vectors induce functionally impaired transgene product–specific CD8+ T cells in miceJCI Insight, 2007
- Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liverBlood, 2007
- Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transferBlood, 2007
- Immune deviation by mucosal antigen administration suppresses gene-transfer–induced inhibitor formation to factor IXBlood, 2006
- Major role of local immune responses in antibody formation to factor IX in AAV gene transferGene Therapy, 2005
- Influence of Vector Dose on Factor IX-Specific T and B Cell Responses in Muscle-Directed Gene TherapyHuman Gene Therapy, 2002